Biotechnology
Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
* Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. * Antengene will receive USD 80 million of upfront and near-term milestone payments, and is e...
2026-03-04 06:00
5867
HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment
SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th An...
2026-03-03 22:30
4767
REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for hum...
2026-03-03 22:00
5388
Efor strengthens its presence in Asia with the acquisition of No deviation
LYON, France, March 3, 2026 /PRNewswire/ -- Efor, a global leader specializing in quality and compliance for the Life Sciences industry, announces the acquisition of Singapore-based No deviation, a company recognized for its expertise in Commissioning, Qualification & Validation (CQV), Computer S...
2026-03-03 09:00
6091
US BioTek Laboratories Completes Merger With NutriPATH Pathology
SEATTLE and MELBOURNE, Australia, March 3, 2026 /PRNewswire/ -- US BioTek Laboratories, a leading functional laboratory specializing in advanced immunological and integrative diagnostics, today announced the completion of its merger with NutriPATH Pathology, a respected functional pathology labo...
2026-03-03 02:15
5494
Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
Australia's Therapeutic Goods Administration (TGA), responsible for approval of the safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk's SKY-0515 orally-administered small molecule therapy for the treatment of Huntington's disease meets TGA eligibility criteria for re...
2026-03-03 01:20
5252
Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver a company presentation at the BIO Investment & Growth Summit. David Bearss, Ph.D., Chief Executive Officer ...
2026-03-02 21:35
3890
Shangpu Group Issues Market Position Statement Recognizing SALIAI's Patented Cellular Essence Global Pioneer
BEIJING and GUANGZHOU, China, March 2, 2026 /PRNewswire/ -- SALIAI ("Guangzhou SALIAI Stem Cell Science and Technology Co., Ltd." and "Guangzhou SALIAI Biological Gene Engineering Co., Ltd.," collectively referred to as "SALIAI") is a China-based biotechnology company engaged in stem cell researc...
2026-03-02 16:14
3396
XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell lymphoma...
2026-03-02 08:30
5815
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis
SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III ...
2026-03-02 08:00
6242
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
* TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in detecting rare genetic diseases * 40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered sta...
2026-02-27 08:00
7868
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more accura...
2026-02-26 16:15
5859
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomi...
2026-02-26 13:54
4860
Discovery linking gut bacteria to cancer treatment wins the Bial Award in Biomedicine and earns €350,000 prize
A study published in Science reveals that a healthy gut microbiota can enhance the efficacy of immunotherapy used to treat cancer, while antibiotics may impair its effect by reducing intestinal microbiota diversity. PORTO, Portugal, Feb. 25, 2026 /PRNewswire/ -- An international consortium of 48...
2026-02-25 22:00
6369
Sanya Yazhou Bay Science and Technology City Appoints Intrinsic SEA as Southeast Asia Strategic Partner Following Landmark Hainan FTP Special Customs Operations
SANYA, China, Feb. 25, 2026 /PRNewswire/ -- Following the historic launch of island-wide independent customs operations in the Hainan Free Trade Port (FTP) onDecember 18, 2025, Sanya Yazhou Bay Science and Technology City (YZBSTC) has entered into a strategic partnership with Intrinsic SEA as its...
2026-02-25 20:18
6107
SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
* New partnership combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platform * Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares' leadership in biosimilars across Latin America ...
2026-02-25 09:00
4559
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
SHANGHAI and HONG KONG, Feb. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune d...
2026-02-25 08:30
4885
Direct Genome-Scale Mapping of Endonuclease Activity of the Human LINE-1 ORF2p Endonuclease
Nabsys and the Research Lab of Dr. Martin Taylor, Brown University, Present Data Using the OhmX™ Platform at AGBT 2026 PROVIDENCE, R.I., Feb. 25, 2026 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping (EGM) technology, today announced new findings presented at the ...
2026-02-25 02:30
5134
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility
40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 24, 2026 /PRN...
2026-02-24 19:36
5214
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agree...
2026-02-24 13:14
4720
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 314 media titles]
2026-05-28 15:06The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 290 media titles]
2026-05-26 10:30
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 289 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 288 media titles]
2026-05-28 10:06Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 287 media titles]
2026-05-27 09:16
Most Read
/DISREGARD RELEASE: Yangzhou Home Ka Crafts Co., Ltd./
2026-05-29 09:19
6434
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
2026-05-26 08:40
5489
NYSE Content Update: Mastercard Celebrates Two Decades as NYSE-Listed Company
2026-05-26 21:04
5390
